Immunosuppressive regimens used for treatment of epoetin-associated pure red cell aplasia
Immunosuppressive reatments . | Dose range . | Route . | Observed recovery, %* . |
|---|---|---|---|
| Cyclophosphamide + prednisone | 50-100 mg/day + 1 mg/kg/day | Oral | 87 |
| Cyclosporine | 100 mg twice/day or 5-8 mg/kg/day | Oral | 67 |
| Prednisone | 1 mg/kg/day | Oral | 56 |
| Intravenous immunoglobulin* | 2 g/kg over 2 to 5 days | Intravenous | 11 |
Immunosuppressive reatments . | Dose range . | Route . | Observed recovery, %* . |
|---|---|---|---|
| Cyclophosphamide + prednisone | 50-100 mg/day + 1 mg/kg/day | Oral | 87 |
| Cyclosporine | 100 mg twice/day or 5-8 mg/kg/day | Oral | 67 |
| Prednisone | 1 mg/kg/day | Oral | 56 |
| Intravenous immunoglobulin* | 2 g/kg over 2 to 5 days | Intravenous | 11 |
Hemoglobin level, reticulocyte counts, and transfusion interval should be monitored over a 4- to 8-week interval. If no hematologic response occurs within 3 to 4 months with initial therapy, a therapeutic trial of a second-line therapy should be considered.
Recovery rates are based on long-term follow-up reported by the European PRCA Study Group for 47 patients with complete follow-up data. 18